Clinical trial · Observational
L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy
Clinical Study of Liquid Tumor Infiltrating Lymphocytes in Patients With Advanced Malignancies Resistance to Anti-PD-1 Therapy
NCT04268108CI-TRIAL-00045507unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| liquid tumor infiltrating lymphocytes | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- group 1
- description
- arm 1: secondary resistance to anti-PD-1 therapy: this patients group received liquid tumor infiltrating lymphocytes combined anti-PD-1 therapy. arm 2: primary resistance to anti-PD-1 therapy: this patients group received FC preconditioning before received liquid tumor infiltrating lymphocytes
- interventionNames
- Biological: liquid tumor infiltrating lymphocytes
Primary outcomes (1)
- measure
- the rate of reverse events
- timeFrame
- three months
- description
- the rate of reverse events
Secondary outcomes (2)
- measure
- clinical benefit rate
- timeFrame
- three months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Expected lifespan is over 3 months * malignant tumors diagnosed by pathological examination * Imaging examination is at advanced stage with at least one measurable lesion * Ineffective or resistant to previous anti-PD-1 therapy * ECOG score 0-2 * Adequate organ function * No other serious diseases that conflict with this protocol * Women of childbearing age must check for a negative blood pregnancy test within 7 days, and subjects of childbearing age must use appropriate contraception during the test and within 3 months * witten informed consent from the patients Exclusion Criteria: * Severe infectious disease within 4 weeks before enrollment * Active hepatitis B or C virus or HIV infection * Severe autoimmune disease or immunodeficiency disease * Severe allergies * Severe mental disorder * Systematically used a large amount of glucocorticoids within 4 weeks before enrollment * With severe heart, liver, kidney insufficiency, diabetes and other diseases * Participation in other clinical studies in the past 3 months or having been treated with other gene products
References
Publications (0)
Data not yet available
No reference posted for this study.